First-in-class antiviral compound against HSV-1 and HSV-2 acyclovir-resistant strains

Patent number:

EP25382332

No items found.

LN-7 is a new endonuclease Inhibitor that prevents Herpes Simplex Virus 1 and 2 (HSV-1 and 2) replication in preclinical in vitro and in vivo studies, postulating as novel antiviral candidate for prevention, conventional antiviral resistant HSV and combination therapy against herpesvirus.

Countries:

Spain

Regions:

Community of Madrid

Centers:

CSIC, UNIVERSIDAD AUTONOMA DE MADRID

Other entities:

Sectors:

Health

Subsectors:

TRL Level:

TRL 4 – technology validated in lab

BRL Level:

PDF Link:

Download here

Video Link:

Watch it here

Sustainable Development Goal:

Applications

• Novel mode of action, different from other antivirals • Prophylactic antiviral effect • Suitable for acyclovir-resistant HSV-1 and HSV-2 • Synergistic activity in combination with acyclovir • Strong candidate for immunocompromised patiens •Safety and efficacy proven in preclinical in vivo models

Comments

Other related patents

Health

ANTISEPTIC COMPOSITION CONTAINING 9-HYDROXYCALABAXANTHONE

Countries

Spain

Health

CAR T/NK-CELLS FOR USE IN THE TREATMENT OF INVASIVE FUNGAL INFECTIONS

Countries

Spain

Health

NUTRITIONAL PREPARATION AS PREVENTATIVE OF PRE AND POST-PARTUM DEPRESSION

Countries

Spain

Get back to patents directory